Cell-Free DNA in Oncology: Gearing up for Clinic

In the past several years, interest in the clinical utility of cell-free DNA as a noninvasive cancer biomarker has grown rapidly. Success in the development of plasma genotyping assays and other liquid biopsy assays has widened the scope of cell-free DNA use in research and the clinic. Already approved by the US Food and Drug Administration in the narrow context of epidermal growth factor receptor-mutated non-small cell lung cancer, plasma genotyping assays are currently being investigated in a wide array of clinical settings and modalities. These include plasma genotyping as a tool for early diagnosis, the detection of minimal residual disease, and the evaluation of treatment response/progression. In this review, we assess the clinical landscape of plasma genotyping assays and propose strategies for their further expansion into routine clinical care.

• Publication year

  2017

• Venue

  Annals of Laboratory Medicine

• Publication date

  2017-10-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.3343/alm.2018.38.1.1PMID 29071812PMCID 5700141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology.

  2018cited by this paper
• "Presence of Fetal DNA in Maternal Plasma and Serum" (1997), by Dennis Lo, et al

  2018cited by this paper
• Phylogenetic ctDNA analysis depicts early stage lung cancer evolution

  2017cited by this paper
• CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA

  2017cited by this paper
• IDH2 Mutation in a Patient with Metastatic Colon Cancer.

  2017cited by this paper
• Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma.

  2016cited by this paper
• Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

  2016cited by this paper
• Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

  2016cited by this paper
• Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

  2016influential reference
• Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Identification of tissue-specific cell death using methylation patterns of circulating DNA

  2016cited by this paper
• Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.

  2016cited by this paper
• A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

  2016cited by this paper
• Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments

  2015cited by this paper
• Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

  2015cited by this paper
• Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

  2015cited by this paper
• Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery

  2015cited by this paper
• Rociletinib in EGFR-mutated non-small-cell lung cancer.

  2015cited by this paper
• Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

  2015cited by this paper
• Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

  2015cited by this paper
• ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

  2015cited by this paper
• Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis.

  2015cited by this paper
• Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.

  2015cited by this paper
• Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

  2015cited by this paper
• Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

  2015influential reference
• Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

  2015cited by this paper
• Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

  2015cited by this paper
• Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.

  2014cited by this paper
• Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection

  2014cited by this paper
• Abstract 5606: Detection of circulating tumor DNA in early and late stage human malignancies

  2014cited by this paper
• Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

  2014cited by this paper
• Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma

  2014cited by this paper
• Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement

  2014cited by this paper
• Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer

  2014cited by this paper
• Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

  2013cited by this paper
• Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

  2013cited by this paper
• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

  2013cited by this paper
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013cited by this paper
• Minimal residual disease in acute myeloid leukaemia

  2013cited by this paper
• The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

  2012cited by this paper
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012cited by this paper
• Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement

  2012cited by this paper
• Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing

  2012cited by this paper
• Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

  2012influential reference
• Detection of ultra-rare mutations by next-generation sequencing

  2012cited by this paper
• Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

  2012cited by this paper
• Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21

  2011cited by this paper
• Detection and quantification of rare mutations with massively parallel sequencing

  2011cited by this paper
• Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement

  2011cited by this paper
• Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing

  2010cited by this paper
• Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer.

  2009cited by this paper
• Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.

  2009cited by this paper
• Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement.

  2008cited by this paper
• Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer.

  2008cited by this paper
• Circulating mutant DNA to assess tumor dynamics

  2008cited by this paper
• TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study.

  2006cited by this paper
• Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

  2003cited by this paper
• Follow-up of patients with curatively resected colorectal cancer: a practice guideline

  2003cited by this paper
• Treatment of recurrent disease in lung cancer.

  2003cited by this paper
• Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years.

  2003cited by this paper
• About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.

  2001cited by this paper
• DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

  2001cited by this paper
• The Origin and Mechanism of Circulating DNA

  2000cited by this paper
• 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines.

  2000cited by this paper
• Digital PCR.

  1999influential reference
• Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma.

  1998cited by this paper
• Presence of fetal DNA in maternal plasma and serum.

  1997cited by this paper
• Les acides nucleiques du plasma sanguin chez l' homme

  1948cited by this paper
• [Not Available].

  1948cited by this paper

• In-matrix library preparation for metagenomic sequencing of microbial cell-free DNA

  2025cites this paper
• Can cell‐free DNA (cfDNA) in pleural lavage serve as a predictive and prognostic biomarker among surgically treated Stage I−III a nonsmall cell lung cancer (NSCLC)? A pilot study

  2024cites this paper
• Cell-free DNA as a plausible biomarker of chronic kidney disease.

  2023cites this paper
• DELFMUT: duplex sequencing-oriented depth estimation model for stable detection of low-frequency mutations

  2023cites this paper
• Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients.

  2023cites this paper
• Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer

  2023cites this paper
• Large-Scale Plasma Proteome Epitome Profiling is an Efficient Tool for the Discovery of Cancer Biomarkers

  2023cites this paper
• The battle against sepsis : exploring the genotypic diversity of pseudomonas and proteus clinical isolates

  2023cites this paper
• Molecular markers in cancer.

  2022cites this paper
• Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors

  2022cites this paper
• The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer

  2022cites this paper
• Comparative of clinical performance between next-generation sequencing and standard blood culture diagnostic method in patients suffering from sepsis.

  2022cites this paper
• Admission Circulating Cell-Free DNA Levels as a Prognostic Factor in Pediatric Burns

  2022cites this paper
• Fragment Size-Based Enrichment of Viral Sequences in Plasma Cell-Free DNA.

  2022cites this paper
• Application of Next Generation Sequencing in Laboratory Medicine

  2021cites this paper
• Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma

  2021influential citation
• Extracellular vesicle molecular signatures characterize metastatic dynamicity in ovarian cancer

  2021cites this paper
• Biomarkers and diagnostic tools for lung cancer

  2021influential citation
• Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma

  2021cites this paper
• Validation of a Circulating Tumor DNA‐Based Next‐Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing

  2021cites this paper
• Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges

  2021cites this paper
• Role of Cell-Free DNA and Deoxyribonucleases in Tumor Progression

  2021cites this paper
• Extracellular Vesicle Molecular Signatures Characterize Metastatic Dynamicity in Ovarian Cancer

  2021cites this paper
• Plasma cell-free DNA for screening patients with benefit-assisted neoadjuvant chemotherapy for advanced gastric cancer

  2020cites this paper
• The Monitoring of Donor-Derived Cell-Free DNA (ddcfDNA) in Kidney Transplantation.

  2020cites this paper
• Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing: A Big Chapter in the Tale

  2020cites this paper
• Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?

  2020cites this paper
• Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA

  2020cites this paper
• Association of clinical, instrumental and molecular genetic predictors with the risk of development and tumor progression of melanocytic intraocular neoplasms

  2020cites this paper
• Clinical Use of Cell-Free DNA in Tumor Diagnostics

  2019cites this paper
• Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts [ version 1 ; peer review : awaiting

  2019cites this paper
• Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.

  2019cites this paper
• Clinical applications of liquid biopsies for early lung cancer detection.

  2019cites this paper
• Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts

  2019cites this paper
• Utilization of Archived Plasma to Detect Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer Patients

  2019cites this paper
• Circulating DNA and Protein Biomarkers for the Treatment of Metastatic Colorectal Cancer with Tyrosine Kinase Inhibitors

  2019cites this paper
• Somatic Testing: Implications for Targeted Treatment.

  2019cites this paper
• Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy

  2019cites this paper
• DNA Methylation Cancer Biomarkers: Translation to the Clinic

  2019cites this paper
• Investigation of the Molecular Diagnostic Market in Animals

  2019cites this paper
• THE PURDUE UNIVERSITY GRADUATE SCHOOL STATEMENT OF DISSERTATION APPROVAL

  2018cites this paper
• Advances in liquid biopsy approaches for early detection and monitoring of cancer

  2018cites this paper
• Liquid biopsy: novel technologies and clinical applications

  2018cites this paper
• Non-invasive assessment of tumor PD-L1 status with circulating tumor cells.

  2018cites this paper
• Cell-Free DNA: Applications in Different Diseases.

  2018cites this paper
• The antioxidant effect of Brazil nut (Bertholletia excelsa) is influenced by a genetic superoxide-hydrogen peroxide imbalance in healthy humans

  2018cites this paper